Powder: -20°C for 3 years | In solvent: -80°C for 1 year
STAT3-IN-13 是一种有效的 STAT3 抑制剂。STAT3-IN-13 具有抗增殖和抗癌活性,通过与 STAT3 SH2 结构域结合发挥作用。STAT3-IN-13 抑制 STAT3 Y705 的磷酸化,诱导细胞凋亡 ,抑制肿瘤细胞的生长和转移。STAT3-IN-13 可用于研究乳腺癌和肝癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,960 | 现货 | ||
5 mg | ¥ 3,320 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,920 | 现货 | ||
50 mg | ¥ 8,950 | 现货 | ||
100 mg | ¥ 11,600 | 现货 |
产品描述 | STAT3-IN-13 is a potent STAT3 inhibitor.STAT3-IN-13 has antiproliferative and anticancer activity and acts by binding to the structural domain of STAT3 SH2.STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705, which induces apoptosis and inhibits tumor cell growth and metastasis.STAT3-IN-13 can be used to study breast cancer and liver cancer. The study of breast cancer and hepatocellular carcinoma. |
靶点活性 | MG63 cell:0.55 μM, 143B:0.25 μM, HOS:0.11 μM, STAT3:0.96 μM (Kd) |
体外活性 | STAT3-IN-13 (compound 6f), over a period of 48 hours, demonstrates anti-proliferative activity with IC50 values of 0.25, 0.11, and 0.55 μM for 143B, HOS, and MG63 cells, respectively [1].In the concentration range of 0.001-100 μM, STAT3-IN-13 (compound 6f) binds to STAT3 and interacts with STAT3^586-685 in a concentration-dependent manner, with a KD of 0.96 μM [1].Over a period of 24 hours at concentrations ranging from 0 to 1.0 μM in 143B and HOS cells, STAT3-IN-13 (compound 6f) inhibits STAT3 Y705 phosphorylation and suppresses STAT3 in tumor cells [1].At concentrations ranging from 0 to 1.0 μM over 48 hours in 143B cells, STAT3-IN-13 (compound 6f) induces apoptosis in a dose-dependent manner [1]. |
体内活性 | In vivo, STAT3-IN-13 (compound 6f), administered intraperitoneally at doses of 10-20 mg/kg twice daily for 4 weeks in nude mice, effectively blocks osteosarcoma growth and metastasis [1]. |
分子量 | 436.49 |
分子式 | C21H20N6O3S |
CAS No. | 2248552-86-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (183.28 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.291 mL | 11.455 mL | 22.91 mL | 57.2751 mL |
5 mM | 0.4582 mL | 2.291 mL | 4.582 mL | 11.455 mL | |
10 mM | 0.2291 mL | 1.1455 mL | 2.291 mL | 5.7275 mL | |
20 mM | 0.1146 mL | 0.5728 mL | 1.1455 mL | 2.8638 mL | |
50 mM | 0.0458 mL | 0.2291 mL | 0.4582 mL | 1.1455 mL | |
100 mM | 0.0229 mL | 0.1146 mL | 0.2291 mL | 0.5728 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
STAT3-IN-13 2248552-86-3 JAK/STAT signaling Stem Cells STAT Inhibitor inhibitor inhibit